• Clinical development


IO103 is a peptide vaccine containing an XX-mer PD-L1-derived peptide.


First phase I trial in Multiple Myeloma (monotherapy) has shown encouraging safety data, and currently two trials are ongoing 

  • Phase I/II trial in Melanoma in combination with Nivolumumab
  • Phase II trial in Follicular lymphoma in combination with IO113